Crown Bioscience announced today that it has restructured its commercial leadership team by creating a new Chief Business Officer (CBO) role and with additional investment in commercial talent.
Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the...
Upgraded facility increases capacity for in vivo services by 30 percent and adds high frequency ultrasound capabilities to the company’s preclinical capabilities
Upgraded facility increases capacity for in vivo services by 30 percent and adds high frequency ultrasound capabilities to the Company’s preclinical capabilities
Platform combining phenotypic high content imaging analysis and three-dimensional models of fresh patient tumors to provide relevant analysis of drug responses that can inform candidate selection a...
Platform combining phenotypic high content imaging analysis and three-dimensional models of fresh patient tumors to provide relevant analysis of drug responses that can inform candidate selection a...
Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
3 of 11
Receive JSR Life Sciences news on your RSS reader.
